Payment overview · 2025
General Payments
$504.95
25 reported records · 11 companies
Healthcare provider profile · identity verified
Fara Nadal, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1659343796
Verified facts
What the public records show
CMS Open Payments records show Fara Nadal, MD received $504.95 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.94 | 21.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.96 | 17.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.97 | 12.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.15 | 10.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.62 | 8.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.77 | 8.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.83 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.84 | 4.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $23.74 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.31 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.82 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $504.95 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.96 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.36 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.15 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.94 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 456 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 129 |
| Omeprazole | Omeprazole | 332 | 105 |
| Lisinopril | Lisinopril | 325 | 89 |
| Alprazolam | Alprazolam | 319 | 76 |
| Losartan Potassium | Losartan Potassium | 318 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 93 |
| Gabapentin | Gabapentin | 285 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 280 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 258 | 82 |
| Potassium Chloride | Potassium Chloride | 255 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 224 | 103 |
| Sertraline Hcl | Sertraline Hcl | 200 | 60 |
| Furosemide | Furosemide | 188 | 56 |
| Trazodone Hcl | Trazodone Hcl | 188 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 40 |
| Tramadol Hcl | Tramadol Hcl | 167 | 50 |
| Metformin Hcl | Metformin Hcl | 161 | 43 |
| Alendronate Sodium | Alendronate Sodium | 160 | 50 |
| Bupropion Xl | Bupropion Hcl | 159 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 42 |
| Meloxicam | Meloxicam | 137 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 42 |
| Montelukast Sodium | Montelukast Sodium | 131 | 49 |
| Simvastatin | Simvastatin | 123 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 32 |
| Metformin Hcl Er | Metformin Hcl | 113 | 33 |
| Prednisone | Prednisone | 111 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 34 |
| Ezetimibe | Ezetimibe | 104 | 32 |
| Allopurinol | Allopurinol | 97 | 27 |
| Estradiol | Estradiol | 97 | 34 |
| Fenofibrate | Fenofibrate | 97 | 27 |
| Spironolactone | Spironolactone | 93 | 32 |
| Mounjaro | Tirzepatide | 88 | 15 |
| Carvedilol | Carvedilol | 84 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 26 |
| Lorazepam | Lorazepam | 82 | 15 |
| Finasteride | Finasteride | 80 | 18 |
| Ibuprofen | Ibuprofen | 76 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 28 |
| Xarelto | Rivaroxaban | 75 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Ozempic | Semaglutide | 68 | 15 |
| Lovastatin | Lovastatin | 67 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 20 |
| Mometasone Furoate | Mometasone Furoate | 65 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 19 |
| Baclofen | Baclofen | 59 | 19 |
| Telmisartan | Telmisartan | 58 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 17 |
| Jardiance | Empagliflozin | 53 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 40 |
| Farxiga | Dapagliflozin Propanediol | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Amoxicillin | Amoxicillin | 48 | 45 |
| Ondansetron Odt | Ondansetron | 48 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 12 |
| Fluconazole | Fluconazole | 46 | 17 |
| Progesterone | Progesterone, Micronized | 46 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Temazepam | Temazepam | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 16 |
| Famotidine | Famotidine | 38 | 14 |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Methocarbamol | Methocarbamol | 37 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Diazepam | Diazepam | 36 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Anastrozole | Anastrozole | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 15 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 20 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 27 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 26 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 11 |
| Linzess | Linaclotide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Flunisolide | Flunisolide | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Nateglinide | Nateglinide | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $504.95 · 25 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Bimzelx, CAPLYTA, CAPVAXIVE, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, MOUNJARO, OFEV, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, UBRELVY, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error